Rocket Pharmaceuticals, Inc. Overview
Pro stress-test →Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need. The company specializes in developing transformative treatments for complex genetic conditions including cardiovascular and immunological diseases.
Strategic Profile
Pro stress-test →Rocket's innovative multi-platform approach allows the company to design the optimal gene therapy for each indication, creating potentially transformative options. With $188.9 million in cash and investments as of December 31, 2025, the company is positioned to fund operations into Q2 2027 while advancing key pipeline programs including a near-term FDA decision on KRESLADI.
Competitive Landscape
Pro stress-test →Rocket operates in the gene therapy space alongside competitors developing treatments for rare genetic disorders. The company differentiates through its multi-platform approach supporting both AAV and lentiviral programs, addressing cardiovascular and immunological indications where few alternatives exist.
Industry Context
Rocket Pharmaceuticals, Inc. operates in Biotechnology - Gene Therapy.
Key facts
Founded: 2011 · Headquarters: Cranbury, US · Employees: N/A · Revenue: N/A · Market cap: $490M-$544M